Spots Global Cancer Trial Database for gemtuzumab ozogamicin
Every month we try and update this database with for gemtuzumab ozogamicin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | NCT00798213 | Leukemia, Myelo... Lymphoblastic L... | SCH 727965 Gemtuzumab ozog... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | NCT04070768 | Acute Myeloid L... | Gemtuzumab Ozog... Venetoclax | 18 Years - | Big Ten Cancer Research Consortium | |
| Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00577694 | Leukemia | clofarabine gemtuzumab ozog... | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia | NCT00089050 | Leukemia | cyclosporine gemtuzumab ozog... | 60 Years - | Fred Hutchinson Cancer Center | |
| Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | NCT00460447 | Acute Myeloid L... Allogeneic Tran... | Gemtuzumab Ozog... | 18 Years - 70 Years | University Hospital Carl Gustav Carus | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | NCT03900949 | Acute Myeloid L... | Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Gemtuzumab in Treating Patients With Myelodysplastic Syndrome | NCT00022321 | Myelodysplastic... | gemtuzumab ozog... | 18 Years - | National Cancer Institute (NCI) | |
| Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | NCT03900949 | Acute Myeloid L... | Allogeneic Hema... Cytarabine Daunorubicin Hy... Gemtuzumab Ozog... Midostaurin | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| AflacLL1901 (CHOA-AML) | NCT04326439 | Acute Myeloid L... AML, Childhood | Cytarabine Daunorubicin Erwinase Etoposide Gemtuzumab ozog... Stem cell trans... Sorafenib | - 21 Years | Emory University | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | NCT00454480 | Leukemia Myelodysplastic... | alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ... | - | National Cancer Institute (NCI) | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | NCT03568994 | Acute Myeloid L... | Atovaquone Cytarabine Daunorubicin Etoposide Gemtuzumab Ozog... | 1 Month - 20 Years | Baylor College of Medicine | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | NCT05955261 | Acute Myeloid L... | Venetoclax Azacitidine Cytarabine Gemtuzumab Ozog... Daunorubicin Hy... Fludarabine Pho... Idarubicin Hydr... Mitoxantrone Hy... Etoposide Gilteritinib | 29 Days - 21 Years | St. Jude Children's Research Hospital | |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00052299 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | NCT01409161 | Acute Promyeloc... | Arsenic Trioxid... Gemtuzumab Ozog... Laboratory Biom... Tretinoin | 10 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | NCT00962767 | Leukemia, Myelo... | gemtuzumab ozog... ATRA plus 6-MP ... | 18 Years - 61 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | NCT04385290 | Acute Myeloid L... | MODULE: convent... MAGNOLIA-trial:... MAGNOLIA-trial:... MAGMA-trial:GO ... MAGMA-trial: co... | 18 Years - 75 Years | Technische Universität Dresden | |
| CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse | NCT00003131 | Leukemia | chemotherapy gemtuzumab ozog... | 18 Years - | Pfizer | |
| Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia | NCT00005962 | Leukemia | sargramostim cyclophosphamid... cytarabine gemtuzumab ozog... liposomal dauno... topotecan hydro... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | NCT00233909 | Leukemia, Myelo... | Zosuquidar gemtuzumab ozog... | 18 Years - | Kanisa Pharmaceuticals | |
| All-trans Retinoic Acid, and Arsenic +/- Idarubicin | NCT00413166 | Acute Promyeloc... | All-Trans Retin... Arsenic Trioxid... Idarubicin Gemtuzumab Ozog... | - | M.D. Anderson Cancer Center | |
| NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | NCT00476541 | Acute Myeloid L... | Gemtuzumab ozog... | 1 Day - 18 Years | University of Aarhus | |
| Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | NCT00037583 | Acute Myeloid L... | Gemtuzumab Ozog... | 18 Years - 59 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | NCT00085709 | Leukemia | gemtuzumab ozog... observation Cytosine arabin... Daunomycin | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | NCT04207190 | Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Quality-of-Life... Questionnaire A... Talazoparib Talazoparib Tos... | 18 Years - | Roswell Park Cancer Institute | |
| CPX-351+GO in Subjects 55 Years Old, or Older, With AML | NCT03878927 | Acute Myeloid L... | CPX-351 Gemtuzumab Ozog... | 55 Years - | Weill Medical College of Cornell University | |
| Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | NCT00028899 | Leukemia Myelodysplastic... | asparaginase cytarabine gemtuzumab ozog... mitoxantrone hy... | - 21 Years | Children's Oncology Group | |
| S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT00049179 | Leukemia | cytarabine gemtuzumab ozog... | 18 Years - | SWOG Cancer Research Network | |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | NCT05558124 | Acute Myeloid L... | Vyxeos Gemtuzumab Ozog... | 18 Years - 70 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse | NCT00003673 | Leukemia | chemotherapy gemtuzumab ozog... | 60 Years - | Pfizer | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | NCT00017589 | Leukemia | oblimersen sodi... gemtuzumab ozog... | 60 Years - | National Cancer Institute (NCI) | |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | NCT01409161 | Acute Promyeloc... | Arsenic Trioxid... Gemtuzumab Ozog... Laboratory Biom... Tretinoin | 10 Years - | M.D. Anderson Cancer Center | |
| AflacLL1901 (CHOA-AML) | NCT04326439 | Acute Myeloid L... AML, Childhood | Cytarabine Daunorubicin Erwinase Etoposide Gemtuzumab ozog... Stem cell trans... Sorafenib | - 21 Years | Emory University | |
| Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy | NCT00070174 | Leukemia | asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide gemtuzumab ozog... methotrexate mitoxantrone hy... allogeneic bone... | - | Children's Oncology Group | |
| Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia | NCT00006122 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00372593 | Leukemia | asparaginase cytarabine daunorubicin hy... etoposide gemtuzumab ozog... mitoxantrone hy... | - 29 Years | Children's Oncology Group | |
| Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00052299 | Leukemia | cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy... | 61 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | NCT00017589 | Leukemia | oblimersen sodi... gemtuzumab ozog... | 60 Years - | National Cancer Institute (NCI) | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy | NCT00070174 | Leukemia | asparaginase busulfan cyclophosphamid... cyclosporine cytarabine daunorubicin hy... etoposide gemtuzumab ozog... methotrexate mitoxantrone hy... allogeneic bone... | - | Children's Oncology Group | |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | NCT01020539 | Acute Myelogeno... Myelodysplastic... Juvenile Myelom... | Fludarabine Busulfan GVHD Prophylaxi... Gemtuzumab Ozog... Anti-Thymocyte ... Isotretinoin | 1 Month - 30 Years | Columbia University | |
| Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | NCT00895934 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... | vorinostat gemtuzumab ozog... azacitidine | 50 Years - | National Cancer Institute (NCI) | |
| Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission | NCT00962767 | Leukemia, Myelo... | gemtuzumab ozog... ATRA plus 6-MP ... | 18 Years - 61 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | NCT00038831 | Acute Myelogeno... Myelodysplastic... Chronic Lymphoc... | Mylotarg Fludarabine Melphalan Anti-thymocyte ... Stem cell trans... | 12 Years - 75 Years | M.D. Anderson Cancer Center | |
| Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | NCT01548911 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | NCT05955261 | Acute Myeloid L... | Venetoclax Azacitidine Cytarabine Gemtuzumab Ozog... Daunorubicin Hy... Fludarabine Pho... Idarubicin Hydr... Mitoxantrone Hy... Etoposide Gilteritinib | 29 Days - 21 Years | St. Jude Children's Research Hospital | |
| Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00673153 | Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Untreated Adult... | gemtuzumab ozog... vorinostat laboratory biom... | 60 Years - | Fred Hutchinson Cancer Center | |
| Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT00008151 | Leukemia Myelodysplastic... | cyclosporine fludarabine pho... gemtuzumab ozog... methotrexate mycophenolate m... allogeneic bone... peripheral bloo... radiation thera... | - | Fred Hutchinson Cancer Center | |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | NCT01869803 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Recurrent Adult... Recurrent Child... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | NCT03672539 | Acute Myeloid L... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Liposome-encaps... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | NCT00669890 | Acute Myeloid L... Juvenile Myelom... Myelodysplastic... | Gemtuzumab Ozog... Busulfan Cyclophosphamid... Thymoglobulin Tacrolimus Mycophenolate M... Methotrexate | - 30 Years | New York Medical College | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | NCT00882102 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | NCT00049517 | Leukemia | sargramostim busulfan cyclophosphamid... cytarabine gemtuzumab ozog... Daunorubicin Autologous HCT Allogeneic HCT | 16 Years - 60 Years | Eastern Cooperative Oncology Group | |
| CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | NCT03904251 | Acute Myelogeno... | Gemtuzumab Ozog... Liposome-encaps... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | NCT03531918 | Acute Myeloid L... | Cladribine Cytarabine Gemtuzumab Ozog... Recombinant Gra... Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| SCT Plus Immune Therapy in Average Risk AML/MDS | NCT02117297 | Acute Myelogeno... Myelodysplastic... | Gemtuzumab Ozog... | - 25 Years | New York Medical College | |
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | NCT00798213 | Leukemia, Myelo... Lymphoblastic L... | SCH 727965 Gemtuzumab ozog... | 18 Years - | Merck Sharp & Dohme LLC | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00091234 | Leukemia | gemtuzumab ozog... | 61 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT00006265 | Leukemia | ara-C gemtuzumab ozog... | 17 Years - | Alliance for Clinical Trials in Oncology | |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | NCT01869803 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Recurrent Adult... Recurrent Child... | gemtuzumab ozog... laboratory biom... | 18 Years - | Wake Forest University Health Sciences | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML | NCT04168502 | Acute Myeloid L... | Glasdegib Gemtuzumab Ozog... | 18 Years - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | NCT04207190 | Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Quality-of-Life... Questionnaire A... Talazoparib Talazoparib Tos... | 18 Years - | Roswell Park Cancer Institute | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | NCT00143975 | Leukemia, Myelo... | Cytarabine Mitoxantrone Gemtuzumab Ozog... All-trans-Retin... | 18 Years - 60 Years | University of Ulm | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
